Evidence map›Paper›PMID 42305821›Full record

ArticleDrug design, development and therapy2026

Identification of Antibacterial Hits Associated with Penicillin-Binding Protein 2 in

Haoyu Zhu, Shijie Du, Qin Yang, Lu Xu, Wei Shi

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haoyu ZhuCollege of Material and Chemical Engineering, Tongren University, Tongren, Guizhou, People's Republic of China.
Shijie DuCollege of Material and Chemical Engineering, Tongren University, Tongren, Guizhou, People's Republic of China.
Qin YangSchool of Physics and Optoelectronic Engineering, Yangtze University, Jingzhou, Hubei, People's Republic of China.
Lu XuCollege of Material and Chemical Engineering, Tongren University, Tongren, Guizhou, People's Republic of China.ORCID 0000-0003-4742-5623
Wei ShiCollege of Material and Chemical Engineering, Tongren University, Tongren, Guizhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Early-stage antibacterial candidate selection requires balancing antibacterial activity with broader developability-related properties. This study developed and applied a Fivefold Maximum Drug-Likeness strategy (5F-MDL) for prioritizing antibacterial candidates against Methods: An ensemble of deep learning models generated a 33-dimensional property spectrum covering physicochemical, pharmacokinetic, efficacy-related, safety, and stability endpoints. Approximately 16 million commercial molecules were screened, and fifteen candidates were experimentally evaluated by disk diffusion and broth microdilution. Molecular docking, molecular dynamics simulations, and a Bocillin-FL competition assay examined potential PBP2-associated interactions. Results: The fifteen prioritized candidates showed high property-spectrum similarity to reference antibiotics, with [Formula: see text] scores ranging from 0.929 to 0.971. Broth microdilution identified several molecules with measurable antibacterial activity, among which M2 showed the most balanced overall profile, including an MIC of 25.6 µg/mL and the largest inhibition zone among the candidates. Docking in the 549 Å Conclusion: The 5F-MDL workflow provides a multidimensional property-spectrum-based approach for early-stage antibacterial candidate prioritization. M2 was identified as a preliminary lead-like hit, although its mechanism, safety profile, and broader applicability require further validation.

Indexed as

Anti-Bacterial AgentsEscherichia coliPenicillin-Binding ProteinsDose-Response Relationship, DrugMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureStructure-Activity RelationshipAnti-Bacterial AgentsPenicillin-Binding Proteinsantibacterial discoverydeep learningEscherichia colifivefold maximum drug-likenesspenicillin-binding protein 2virtual screening

Identifiers

PMID42305821
PMCPMC13265263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.